Clinical Cancer Research

Papers
(The H4-Index of Clinical Cancer Research is 66. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Selected Articles from This Issue406
Selected Articles from This Issue245
Selected Articles from This Issue222
And… We’re Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring205
Project Optimus Elicits the “Holistic” Benefits of PK/PD Modeling of Immunotherapy204
Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation196
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls194
Abstract C025: Endometrial cancer mutation patterns by age with possible increased TP53 and decreased PTEN mutations in patients 50+ years old182
In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer166
CH Mutations in 16,812 Advanced Cancer Patients–Response157
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study156
Abstract B036: Non-steroidal anti-inflammatory drugs use and risk of colorectal cancer molecular subtypes: A systematic review and meta-analysis142
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma139
Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations132
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer131
Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities127
SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection126
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma126
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer123
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial122
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication119
UBE2T-Mediated HP1α Ubiquitination Enhances Nucleolar Function and Promotes the Progression of IDH1/TP53-Mutant Glioma113
A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1110
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study108
Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma107
Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study106
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy105
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas102
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair101
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer99
Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas96
Abstract PS2-07-19: Proteomic subtyping of stage II/III TNBC from the I-SPY2 TRIAL reveals a druggable steroid hormone receptor signature (SRS) that is associated with poor outcome and enriched in non92
Abstract PS2-08-09: Baseline HER2 expression on circulating tumor cells in metastatic breast cancer91
Abstract PS1-13-04: Fairness-constrained logistic regression achieves superior performance and racial equity in breast cancer survival prediction90
Abstract PS2-04-10: Adherence to endocrine prevention in patients with atypical hyperplasia and lobular carcinoma in situ: promising trends from real-world use of low dose tamoxifen85
Abstract PS2-07-21: Tumor Necrosis Factor-related Weak Inducer of Apoptosis (TWEAK) - A Potential Biomarker for Predicting Response and Long-Term Outcomes in Early Breast Cancer Patients85
Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection83
Abstract PS3-03-18: Guidelines for Breast Cancer Index Test before and after Epic software enhancement83
Abstract PS2-10-18: Epithelial-mesenchymal transition (EMT) Signature Score of a Bulk Tumor May Not Reflect the EMT of Malignant Epithelial Cells82
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer81
Abstract PS3-07-12: The CONCISE Study : A Pan-UK Real-World Audit of Adjuvant Abemaciclib Use in High-Risk Early Breast Cancer81
Selected Articles from This Issue81
Abstract PS5-10-21: Real-world patterns and preferences in the use of diagnostic imaging for breast cancer staging in Hispano-America: A multinational physician survey81
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia80
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma78
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research77
Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships76
Learning Individual Survival Models from PanCancer Whole Transcriptome Data76
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma76
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial74
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma74
The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma74
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group74
Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas73
Abstract PS5-12-26: Yoga in Breast Cancer Survivorship: Knowledge, Attitudes, <Perceived Benefits73
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality73
Abstract RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Subst73
Abstract PS5-05-25: Is the 21-Gene Recurrence Score Validated for Real-World use in Node Positive Breast Cancer? A Retrospective Cohort Study72
Abstract PS5-08-15: Targeted axillary dissection vs axillary node clearance in patients with positive axillary nodes in early breast cancer: a multicentre, pragmatic, phase 3 randomised controlled tri72
Abstract PS5-12-10: Impact of KEYNOTE-522 on BneoCT: An Institutional Quality Measure Improvement Analysis71
Abstract PS5-07-29: Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients wit70
Abstract PS5-12-05: Cdk4/6 inhibitors in outpatient gynecological oncology: identification of implementation barriers and opportunities for improving their use in the practice70
Abstract PS4-02-26: Gper signaling as a biomarker for endocrine therapy sensitivity in pik3ca mutant hr+ advanced breast cancer68
Abstract PS2-01-07: A Multicenter Retrospective Observational Study on the Safety and Timing of Radiotherapy After Oncoplastic Breast-Conserving Surgery67
PS4-05-22: Eprs1 induces ac4c modification of mRNAs encoding pluripotency factors in breast cancer cells67
Abstract PS1-13-10: Elucidating Stemness-Associated Regulatory Pathways to Guide Personalized Treatment for Ductal Carcinoma in Situ67
Abstract PS3-11-18: Neoadjuvant Response in HER2+ Early Breast Cancer: A Comparative Study Between HER2-Enriched and Luminal HER2 Subtypes66
Abstract PS2-05-06: Safety and Oncologic Outcomes of Immediate Breast Reconstruction Following Neoadjuvant Chemotherapy66
Abstract PS4-02-09: Symptom Clustering and Multi-Omics Signatures of Cancer-Related Fatigue in Breast Cancer: Findings from the China PERSEVERE Cohort66
0.084989070892334